Literature DB >> 15090428

Cannabinoids and glaucoma.

I Tomida1, R G Pertwee, A Azuara-Blanco.   

Abstract

Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable. Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15090428      PMCID： PMC1772142          DOI： 10.1136/bjo.2003.032250

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


  58 in total

1.  CB1 cannabinoid receptor induction in experimental stroke.

Authors:  K L Jin; X O Mao; P C Goldsmith; D A Greenberg
Journal:  Ann Neurol       Date:  2000-08       Impact factor: 10.422

2.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

Authors:  M Shen; S A Thayer
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

3.  Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits.

Authors:  Krista Laine; Kristiina Järvinen; Tomi Järvinen
Journal:  Life Sci       Date:  2003-01-03       Impact factor: 5.037

Review 4.  Cannabinoid receptors and pain.

Authors:  R G Pertwee
Journal:  Prog Neurobiol       Date:  2001-04       Impact factor: 11.685

5.  Antagonism of arachidonic acid-induced ocular effects by delta1-tetrahydrocannabinol.

Authors:  K Green; S M Podos
Journal:  Invest Ophthalmol       Date:  1974-06

6.  Interaction between delta-9-tetrahydrocannabinol and indomethacin.

Authors:  K Green; E C Kearse; O L McIntyre
Journal:  Ophthalmic Res       Date:  2001 Jul-Aug       Impact factor: 2.892

Review 7.  The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology?

Authors:  I O Haefliger; P Meyer; J Flammer; T F Lüscher
Journal:  Surv Ophthalmol       Date:  1994 Sep-Oct       Impact factor: 6.048

8.  A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits.

Authors:  N Naveh; C Weissman; S Muchtar; S Benita; R Mechoulam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-04       Impact factor: 3.117

Review 9.  Neuroprotective antioxidants from marijuana.

Authors:  A J Hampson; M Grimaldi; M Lolic; D Wink; R Rosenthal; J Axelrod
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

10.  Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man.

Authors:  K Green; M Roth
Journal:  Arch Ophthalmol       Date:  1982-02
View more
  41 in total

1.  Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Authors:  Ketan Hippalgaonkar; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

2.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 3.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation.

Authors:  Ketan Hippalgaonkar; Goutham R Adelli; Kanchan Hippalgaonkar; Michael A Repka; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-19       Impact factor: 2.671

Review 6.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

7.  Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.

Authors:  Rachelle Abouchedid; James H Ho; Simon Hudson; Alison Dines; John R H Archer; David M Wood; Paul I Dargan
Journal:  J Med Toxicol       Date:  2016-07-25

8.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

9.  Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.

Authors:  B T McIntosh; B Hudson; S Yegorova; C A B Jollimore; M E M Kelly
Journal:  Br J Pharmacol       Date:  2007-10-08       Impact factor: 8.739

10.  [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.

Authors:  H Donald Burns; Koen Van Laere; Sandra Sanabria-Bohórquez; Terence G Hamill; Guy Bormans; Wai-si Eng; Ray Gibson; Christine Ryan; Brett Connolly; Shil Patel; Stephen Krause; Amy Vanko; Anne Van Hecken; Patrick Dupont; Inge De Lepeleire; Paul Rothenberg; S Aubrey Stoch; Josee Cote; William K Hagmann; James P Jewell; Linus S Lin; Ping Liu; Mark T Goulet; Keith Gottesdiener; John A Wagner; Jan de Hoon; Luc Mortelmans; Tung M Fong; Richard J Hargreaves
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.